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Abstract
One of the most neglected areas of everyday clinical practice for HIV physicians is unexpectedly represented by
CD4 T cell counts when used as an aid to clinical decisions. All who care for HIV patients believe that CD4+ T cell
counts are a reliable method to evaluate a patient immune status. There is however a fatalistic acceptance that
besides its general usefulness, CD4+ T cell counts have relevant clincal and immunological limits. Shortcomings of
CD4 counts appear in certain clinical scenarios including identification of immunological nonresponders,
subsequent development of cancer on antiretroviral teatment, failure on tretment simplification. Historical and
recently described parameters might be better suited to advise management of patients at certain times during
their disease history. Immunogenotypic parameters and innate immune parameters that define progression as well
as immune parameters associated with immune recovery are available and have not been introduced into
validation processes in larger trials. The scientific and clinical community needs an effort in stimulating clinical
evolution of immunological tests beyond “CD4saurus Rex” introducing new parameters in the clinical arena after
appropriate validation
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Introduction
Basic biomedical research is crucial for understanding
pathogenetic mechanisms of diseases, as well as to
develop new techniques drugs or concepts aimed at
improving patient clinical care. Clinical implications of
basic research are regularly reported in major journals
in an effort to improve the transfer of benchwork into
bedside clinical practices[1], and whenever promising
steps in basic research fail to be introduced, this is
underscored [2].
After the identification of CD4+ T cells as the main
target HIV replication, scientists focused on several
important issues, including pathogenesis of mucosal
infection[3-8], clearance of residual replication[9-13],
evaluation of the involvement of innate immunity in dis-
ease progression[14-16], and identification of immunolo-
gical correlates of protection for vaccine studies[17-20].
New cell subsets, receptors, cytokines, and signaling
pathways were described [16,21-25], and widely available
techniques for the ex vivo study of cells of the innate
immune system (e.g. pDC, mDC, NK cells, NKTcells) or
of Toll-like receptors were introduced. Models of HIV
pathogenesis have been upgraded to account for and
adjust to the new players and their functional character-
istics. By “CD4” we now define at least 5 different CD4+
T-cell lineages, central and peripheral memory cells
with variable effector functions (Figure 1). Evolution of
our understanding of CD4+ T-cell type and function
had however little impact on the Jurassik Park of clinical
HIV care and antiretroviral trials. In the majority of
cases, indeed, “immunology” is still represented by
“quantitative determination of CD4+ T-cell numbers”
alone to assess the immune status of routine patients
attending HIV clinics.
CD4saurus Rex: a relic from old times
For some reason, apparently unexplained factors
prevented our clinical practice from evolving moving
* Correspondence: de-maria@unige.it
1Centro di Eccellenza per la Ricerca Biomedica, Università di Genova,
Genova, Italy
Full list of author information is available at the end of the article
De Maria and Cossarizza Journal of Translational Medicine 2011, 9:93
http://www.translational-medicine.com/content/9/1/93
© 2011 De Maria and Cossarizza; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the
Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.
from discussing patients in terms of CD4+ T-cell counts
alone to including additional specific tests. Clinical
activity and knowledge has evolved rapidly in the same
field leading to inclusion in everyday clinical life of
DExa, PK/PD, ultrasensitive viral load, phenotypic and
genotypic resistance evaluation. When it however comes
to immunology, clinicians stick to a very successful but
Jurassic test like CD4+ T-cell counts, which for the
moment we could nickname “CD4saurus Rex“. Unlike
real Dinosaurs, CD4+ cell count and its clinical use has
neither evolved/upgraded nor vanished each time a clin-
ician is assessing a patient immune status before taking
critical decisions with HIV patients.
There are few doubts that absolute CD4+ T cell
counts have served, and still serve, as a very robust sur-
rogate for progression to AIDS or death. They correlate
generally well to the level of immune competence of
patients with[26,27] or without[28] HIV infection, and
also in children [29].
Proof of the robustness of this relic of immunologi-
cal evolution is represented by its extensive use as a
surrogate marker of immune competence to stratify or
select patients in all recent trials evaluating or licen-
sing the use of newer drug classes or ART regimens
and in studies assessing the optimal time for ART
initiation.
Even in the quest to identify additional risk factors for
HIV-associated non-AIDS defining diseases, including
nephropathy of cardiovascular disease, CD4+ T cell
counts are the only immune parameter used to stratify
patient cohorts[30,31].
Shortcomings of CD4saurus Rex
The concept of CD4+ counts as clinical surrogate mar-
kers is still valid today and should continue to be used
in routine patient follow-up. However, there are areas of
clinical experience where it falls short of our needs.
Opportunistic infections may be sometimes observed
in patients presenting with CD4+ T cell counts well
above the critical range usually referred to for a given
infection, as is the case for PML, TB[32-34], lymphoma
[35] or Kaposi sarcoma patients who may unexpectedly
present with relatively high CD4+ T cell numbers in the
300-400/μl range[36]. Conversely, at any given CD4+
cell count stratum, a fraction of patients have chances
to develop PML, TB, lymphoma or KS, but CD4+ cell
counts alone do not help us to further narrow down our
attention on those who will actually develop disease. A
surprisingly sustained incidence of HPV-associated
pathology (e.g., cervical carcinoma, anal carcinoma) is
observed even after successful ART with rising CD4+
cell counts[37,38]. Drug simplification to lopinavir/rito-
navir monotherapy is effective at 96 weeks, but only in a
subset of patients (47%) not identified by CD4
+standards at baseline.[39].
These events are apparently unexplained to the clini-
cian each time they are observed and are usually
accepted as one would accept a rainy day. Other factors
in the immune playground are likely to be involved, but
“CD4saururs Rex“ still grabs center stage, and we are
missing part of the picture.
Treatment interruptions guided by the number of
CD4+ T cells (CD4+GTI) have been lately discouraged
by studies that showed significant risk of disease pro-
gression to AIDS or death or of cardiovascular events in
patients selected on a narrow and low range of CD4+ T
cells (i.e.350-200 CD4+/μl) [40]. Other studies however
show that CD4+GTI is feasible and bears negligible/no
risks for patients with different characteristics and con-
siderably higher CD4+ cell counts (500-750/μl) [41,42].
Analysis of progressing patients on CD4+GTI shows
that other phenotypic or functional immune variables
beyond CD4+ cell counts (e.g.CD4+ nadir, NK cell phe-
notype[43]) may define the subset of patients for whom
STI of CD4+GTI could be an option.
A similar issue is represented by immunological
discordance on ART, which is observed in about 15-20%
of drug-naïve patients starting ART[44]. Patients and
physicians may develop anxiety over failure to recover
CD4+ cells, over prophylaxis and over the risk of devel-
oping AIDS.
Thus, at the single patient level, which means our
everyday life, we have to cope with an absolute number,
without any other parameter that could help explain
outliers, aid individualized management optimization or
help to predict - or at least express a likelihood
Figure 1 Possible definitions of CD4+ T-cells based on current
knowledge. CD4+ cell counts only represent sums of individual
subsets and do not reflect actual composition. Patients with equal
CD4+ cell counts may reflect different proportional composition
with possibly widely diverging functional immune characteristics.
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-whether a given patient will or will not develop an
unwanted condition/disease course.
What failed on the path of CD4+saurus Rex evolution,
and which options are available
The reasons underlying this “frozen evolution” of immu-
nological tests applied to HIV patients are multifaceted.
Besides the outstanding robustness in terms of wide
availability, standardization, and quality control of
“CD4saurus Rex“, there are few additional assays that
raise some interest and that have been proposed as an
additional qualitative or quantitative measure of the like-
lihood for a patient to develop a specific pattern of pro-
gression or of response to a given treatment.
The drive to improve basic understanding of HIV
associated immune derangements could play a role in
leaving little time and money to refine clinical use of
acquired experience. Competition and a limited propen-
sity of different researchers to integrate techniques
developed elsewhere into clinical practice, also may play
a role in the lack of translation of benchwork into bed-
side assets for patients. The misleading perception that
budget restraints in immune evaluations are justified,
particularly in the absence of wide integration of immu-
nology centers, leaves us with large studies where CD4+
T-cells are the only immune measure, preventing inclu-
sion of additional tests (Figure 2).
Alternative use of qualitative CD4+ T cell analysis,
instead of CD4+ T cell count alone, has been proposed
for other infectious diseases. It is well known that
changes in the phenotype of CD4+ T cells occur in a
large number of viral infections, and can be easily moni-
tored. For example, atypical lymphocytes expressing
CD4+/CD45RO+ may play the role of helper T cells in
the development of the mononucleosis-like syndrome
which is associated with Hepatitis-A infection[45].
During Epstein-Barr infection, a high number of CD4
+Foxp3+ Treg cells can be localized in tonsils, which
are the port of entry of the virus [46], and their role in
inhibiting CD8+ T cell activity is under investigation.
Recently, flow cytometry has also revealed its utility in
providing informative patterns that can differentiate
between infections of bacterial and viral origin. Indeed,
these patterns have been obtained by combining the
fractions of HLA-DR expressing T cell subpopulations
with the level of CD40 on monocytes [47].
Discussion
An improved approach to clinical development of
immune measures should be designed and validated in
the HIV arena. Embedding promising - or rather con-
firmed -immune parameters in new phase III/IV trials
for ART or management optimization would provide a
stimulus for the validation of additional clinical tools
(Table 1). So far, no large study has tried to validate any
of known potential markers which would add clinical
information to CD4+ T-cell counts. These tests, includ-
ing expression of CD38 or CD127, degree of T or NK
cell activation (e.g.:HLA-DR, CD69 or Ki67), NCR
expression by NK cells, or KIR:HLAtyping, could be
used to flag different clinical options or outcomes at dif-
ferent times of the disease/treatment course (e.g.:
immune-reconstitution, ART switch to monotherapy in
selected patients or CD4+GTI, surveillance for unex-
pected opportunistic events including AIDS defining
and non-AIDS defining neoplasms).
In industrialized countries, most laboratories are
equipped with flow cytometers that are able to analyze
routinely multiple (at least 4, up to 8) fluorescent
cellular markers. More sophisticated approaches based
on polychromatic flow cytometry have allowed to iden-
tify a relevant heterogeneity within the CD4+ T cell
Figure 2 Why are we stuck with CD4+ alone to evaluate immune competence of HIV-1 patients?
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compartment [48]. Additional information on the
immunological status of a given patient can be easily
obtained, and should be customized on patient needs.
Testing would not be required on a regular “routine”
basis, but rather could be applied just before a “strate-
gic management decision”, to estimate the likelihood
of a given patient or patient group to have different
clinical outcomes. This would contain costs and pro-
vide optimal use of a dedicated test. For example, con-
cerning management of a drug naïve patient, one of
the main questions would be whether the patient will
become an immunological non-responder. Thus, tests
for assessing the capacity of producing new T-cells, in
terms of thymic functionality (such as the amount of
TREC+cells, IL-7 plasma levels, expression of CD127)
[49-51] could be introduced. Similarly, KIR:HLA car-
riage and IL-28 Bpolymorphisms condition significantly
treatment response during HCV infection[52-54] and
has implications also on disease course in coinfected
patients and possibly bear on response to ART[55-58].
Concerning an advanced patient failing a drug regi-
men, markers of CD8+ T cell activation (such as
CD38, CD95 or MHC class II), differentiation
(CD45RA, CCR7 or CD62L), survival (CD127) and of
CD4 activation and differentiation could be crucial
(Table 1). Similar considerations could be applied to
successfully treated patients with suppressed VL and
recovered CD4+ T cell count, who would candidate for
simplification regimens (or for possible drug vacation
on the basis of NK activating/inhibitory receptor phe-
notype[43] (Table 1). Last but not least, age-related
immunological changes in a huge number of para-
meters, including the subpopulations of CD4+ T cells,
have to be considered when “normal” levels of a bio-
marker are studied, considering that the aging of HIV+
patients is an emerging problem of relevant impor-
tance (50).
Conclusion
In conclusion, time has come to introduce complemen-
tary customized parameters, in addition to CD4+ cell
counts, in the clinical care of HIV-infected patients in
order to provide additional immuno-virological stratifi-
cation criteria. This may be achieved by specifically
investing on appropriate validation/standardization
strategies in clinical trials (extending in range from ART
initiation to ART optimization) using available
parameters
Table 1 List of useful or promising analyses, in addition to CD4+saurus Rex testing, so far unaccounted for in clinical
trial validation but potentially relevant in every-day patient management and clinical decisions
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CCR5-∂32, CCR2-64I At diagnosis. Presence. Slower disease progression, lower VL [71]
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